Oral pilocarpine for radiation-induced xerostomia: Integrated efficacy and safety results from two prospective randomized clinical trials

John W. Rieke(Harper University Hospital), Susan C. Gallagher(Unknown), Mark D. Hafermann(Virginia Mason Medical Center), Jonas T. Johnson(University of Pittsburgh), Charles C. Muscoplat(Harper University Hospital), Barry W. Steiger(Harper University Hospital), Ryan R. Iwamoto(Virginia Mason Medical Center), Francis G. LeVeque(Fred Hutch Cancer Center)
International Journal of Radiation Oncology*Biology*Physics
February 1, 1995
10.1016/0360-3016(94)00361-n
Cited by 139

Related Papers

Oral Mucositis and the Clinical and Economic Outcomes of Hematopoietic Stem-Cell Transplantation
|Journal of Clinical Oncology|2001|682
Oral Pilocarpine for Post-Irradiation Xerostomia in Patients with Head and Neck Cancer
|New England Journal of Medicine|1993|483
The Extracapsular Spread of Tumors in Cervical Node Metastasis
|Archives of Otolaryngology - Head and Neck Surgery|1981|371
A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients.
|Journal of Clinical Oncology|1993|292
Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.
|PubMed|1997|109